LDS/Medical Tests/Prostaglandin D2 (PGD2), Serum

Prostaglandin D2 (PGD2), Serum

Prostaglandin D2 (PGD2) is a bioactive lipid mediator derived from arachidonic acid via the cyclooxygenase (COX) pathway. PGD2 is produced primarily by mast cells, neurons, platelets, and endometrial tissue. It has diverse physiological roles, including modulation of inflammation, smooth muscle tone, sleep regulation, and platelet aggregation.

In the central nervous system, PGD2 functions as a sleep-promoting factor through DP1 receptor activation in the hypothalamus, while also contributing to neuroinflammation via microglial activation. It has been implicated in the pathophysiology of Alzheimer’s disease, where it may promote amyloid-beta plaque deposition, and in Parkinson’s disease, where it contributes to dopaminergic neuron injury.

PGD2 is a potent bronchoconstrictor and plays a central role in allergic diseases such as asthma, allergic rhinitis, and anaphylaxis. In the reproductive system, it participates in regulation of the menstrual cycle, implantation, and uterine contractions, and is associated with preterm labor. Additionally, PGD2 exhibits anti-thrombotic activity, modulates vascular tone, and may have anti-metastatic effects in cancer biology.

  • Aid in the evaluation of allergic and inflammatory conditions (e.g., asthma, allergic rhinitis, anaphylaxis)
  • Assist in assessment of sleep disorders and circadian rhythm dysregulation
  • Useful in evaluation of reproductive health and preterm labor risk
  • As an aid in the diagnosis and monitoring of neurodegenerative disease activity (e.g., Alzheimer’s, Parkinson’s)
  • Useful in evaluation of cardiovascular and bleeding risk
  • Supportive biomarker in traumatic brain injury and neuroinflammation research

Increased in:

  • Alzheimer’s disease
  • Parkinson’s disease
  • Atherosclerosis
  • Rheumatoid arthritis
  • Asthma
  • Allergic rhinitis
  • Preterm labor

Decreased in:

  • Severe combined immunodeficiency disorders (SCID)
  • Chronic fatigue syndrome

35 – 115 pg/mL

Enzyme-linked immunosorbent assay (ELISA) is the standard method. Liquid chromatography–mass spectrometry (LC-MS/MS) may also be used in specialized centers.

Serum, Red top vial.

Specimen should be separated and freeze for transportation and use.

Stability

  • Frozen: 60 days.

Patient should not be on aspirin, indomethacin, or any anti-inflammatory medications for at least 48 hours prior to specimen collection.

Arterial blood gases, complete blood count (CBC), comprehensive metabolic panel, ammonia, S-100B protein, D-dimer, partial thromboplastin time (PTT), vitamin B12, apolipoprotein E genotyping, amyloid-beta protein ratio (Aβ42/Aβ40).
3 to 7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login